Elena Santagostino

Medicine · Health Sciences

60h-index14.8kcitations376works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hemophilia Treatment and Research(318), Platelet Disorders and Treatments(136), Blood Coagulation and Thrombosis Mechanisms(110), Coagulation, Bradykinin, Polyphosphates, and Angioedema(67), Hemostasis and retained surgical items(50)

Publications375 total

Clinical outcomes up to 4 years of once-weekly efanesoctocog alfa prophylaxis in previously treated adults, adolescents, and children with severe hemophilia A: Interim analysis of the Phase 3 XTEND-ed long-term extension study
Blood·2025
HTRS2025.P2.60 SYNOVIIIUS: Prospective Interventional Study of Effectiveness of Efanesoctocog Alfa Prophylaxis for Synovial Hypertrophy in Patients With Hemophilia A — Study Design
Research and Practice in Thrombosis and Haemostasis·2025Open Access
A phase 1, open-label study to assess the pharmacokinetics, safety, and tolerability of a single intravenous injection of efanesoctocog alfa in adults with type 2N or type 3 von Willebrand disease
Journal of Thrombosis and Haemostasis·2025· 2 citedOpen Access
Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND‐1 and XTEND‐Kids Studies
Haemophilia·2025· 3 citedOpen Access
Real-World Effectiveness and Usage of Recombinant Factor IX Fc: Interim Analysis in Paediatric Patients from the 24-Month, Prospective, Non-Interventional B-MORE Study
Hämostaseologie·2025
Perioperative Management with Efanesoctocog Alfa in Adults, Adolescents, and Children with Severe Hemophilia A in the Phase 3 XTEND Clinical Program
Hämostaseologie·2025
Association between Hemophilia Joint Health Score and Quality of Life Using Results from the Xtend-1 Efanesoctocog Alfa Phase 3 Trial
Blood·2024Open Access
Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany
Research and Practice in Thrombosis and Haemostasis·2024· 3 citedOpen Access
Change in Hemophilia Joint Health Score (HJHS) During the Phase 3 XTEND-1 Study of Efanesoctocog Alfa in Patients With Severe Hemophilia A
Hämostaseologie·2024
A post hoc analysis of previously untreated patients with severe hemophilia A who developed inhibitors in the PUPs A-LONG trial
Blood Advances·2024· 1 citedOpen Access
Treatment of Bleeding Episodes with Efanesoctocog Alfa in Children with Severe Hemophilia A in the XTEND-Kids Phase 3 Study
Blood·2023· 1 citedOpen Access
A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one‐stage clotting and chromogenic substrate assays at clinical haemostasis laboratories
Haemophilia·2023· 25 citedOpen Access
PB0195 Efanesoctocog Alfa Versus Emicizumab in the Prophylactic Treatment of Adolescents and Adults with Severe Hemophilia A without Inhibitors: A Matching-Adjusted Indirect Comparison
Research and Practice in Thrombosis and Haemostasis·2023· 1 citedOpen Access
OC 69.5 Outcomes in Adult and Adolescent Patients with Severe Hemophilia a in the Phase 3 XTEND-1 Study Who Switched to Efanesoctocog Alfa Prophylaxis from an Observational Study with Factor VIII Prophylaxis
Research and Practice in Thrombosis and Haemostasis·2023· 1 citedOpen Access
PB0649 Results from the RESIST Study for Tolerance Induction in Patients with Poor Prognosis for ITI Success
Research and Practice in Thrombosis and Haemostasis·2023Open Access
LB 01.1 Efanesoctocog Alfa Prophylaxis for Previously Treated Patients <12 Years of Age with Severe Hemophilia A
Research and Practice in Thrombosis and Haemostasis·2023· 7 citedOpen Access
Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis
Research and Practice in Thrombosis and Haemostasis·2023· 2 citedOpen Access
Pharmacokinetic parameters of recombinant factor IX Fc fusion protein are not influenced by factor IX antigen levels in subjects from the Phase 3 B‐LONG trial
Haemophilia·2022· 5 citedOpen Access
Efficacy of Efanesoctocog Alfa on Pain in Patients with Hemophilia A: Results from the XTEND-1 Phase 3 Clinical Trial in Previously Treated Patients with Hemophilia A
Blood·2022· 1 cited
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B‐LONG using haemophilia‐specific quality of life questionnaires
Haemophilia·2021· 11 citedOpen Access
page 1 of 19Next →

Frequent Co-authors

Pier Mannuccio Mannucci(15), Maria Elisa Mancuso(12), Massimo Morfini(10), Johannes Oldenburg(8), A. Gringeri(8), Cédric Hermans(7), Annarita Tagliaferri(7), Johnny Mahlangu(6), Guy Young(6), Flora Peyvandi(6), Rolf Ljung(6), Víctor Jiménez‐Yuste(6), Angiola Rocino(6), Maria Gabriella Mazzucconi(5), Johanna G. van der Bom(5), Robert Klamroth(5), H. Marijke van den Berg(4), Christoph Male(4), Giancarlo Castaman(4), Karin Fijnvandraat(4)